Adalta Ltd. · ASX:1AD
Adalta — AusBiotech 2019
25 slides from Adalta's conference presentation, Oct 30, 2019
Slide 1: AdAlta presentation to AusBiotech Conference
ASX Announcement AdAlta presentation to AusBiotech Conference For personal use only MELBOURNE Australia, 30 October, 2019: AdAlta Limited (ASX: 1AD), is pleased to release a copy of the presentation that will be delivered today at the AusBiotech 2019 conference. AusBiotech is the leading annual conf
Slide 2: Notes to Editors: About AdAlta
Notes to Editors About AdAlta For personal use only AdAlta Limited is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of protein therapeutics, known as i-bodies, that have the potentia
Slide 3: AusBiotech 2019 conference
For personal use only AusBiote iy | bs 9 30 October - 1 November 2019 Melbourne Convention and Australia’s Life Sciences Conference Exhibition Centre, South Wharf HOST INDUSTRY BODY oh YW @aussiotecH AusBiotech* Hf AUSBIO19 HOST STATE PARTNER, Fou @ _ wwwaussiorecHnc.ore
Slide 4: Anti-fibrotic drugs: A hot area for big pharma
For personal use only Anti-fibrotic drugs: A hot area for big pharma Dr Mick Foley AdAlta Gary Phillips Pharmaxis Dr Nina Webster Dimerix Prof Darren Kelly Certa Therapeutics
Slide 5: Fibrosis: significant unmet medical need
Fibrosis: significant unmet medical need For personal use only • Fibrosis is the build-up of connective tissue - Results from repeated inflammation and uncontrolled wound healing - Causes scarring of vital organs such as the lung, liver, skin, eye, heart and kidney - Leads to irreparable damage and
Slide 6: Fibrosis: multiple indications
Fibrosis: multiple indications For personal use only Heart Eye Wet age-related macular degeneration Cardiac Fibrosis Proliferative vitreoretinopathy Liver Lung Cirrhosis Idiopathic Pulmonary Fibrosis Non-alcoholic steatohepatitis (NASH) Interstitial Lung Disease Kidney Chronic Kidney Disease Skin En
Slide 7: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments Fibrosis assets acquired at an early stage – typically based on Phase I results For personal use only Date Company Target Indication Acquired by Deal value (US$) Development Stage Oct-19 Pliant PLN-1474 Liver Novartis $80m upfront Phase I Therapeutics (+
Slide 8: Australia batting above its average
Australia batting above its average For personal use only PXS-4728A acquired in FT011 inhibited fibrosis of DMX-200 addresses 3 AD-214 shows anti-fibrotic Phase I by BI for NASH kidney and heart mechanisms of kidney and anti-inflammatory fibrosis effects in multiple fibrosis $45m upfront and up to F
Slide 9: Targeting CXCR4 using an i-body: A novel approach to fibrosis
For personal use only Targeting CXCR4 using an i-body: A novel approach to fibrosis Ausbiotech 2019 Mick Foley, CSO AdAlta Limited (ASX:1Ad)
Slide 10: i-body technology
i-body technology For personal use only AdAlta is developing a new technology platform that produces unique proteins known as i- bodies. An i-body is a human protein that combines the advantages of small molecules (stability) and antibodies (high affinity and specificity) in one powerful treatment.
Slide 11: i-bodies: human single domains
i-bodies: human single domains For personal use only Long loop Shark Human Human VNAR Ribbon Overlay NCAM Domain 1 i-body library 9
Slide 12: CXCR4 in fibrosis and other disease states
CXCR4 in fibrosis and other disease states For personal use only Member of the C-X-C family of chemokine receptors Several established functions – Maintaining stem cells in bone marrow (approved CXCR4 antagonist is used to mobilise stem cells but cannot be used chronically due to cardiotoxicity) – H
Slide 13: A CXCR4 i-body with high affinity and specificity
A CXCR4 i-body with high affinity and specificity For personal use only Highly specific: AD-114 tested against 167 GPCRs and selectively binds to CXCR4 AD-114 AD-214 Binds to CXCR4 on Binds to CXCR4 on the cell surface and the cell surface and has anti-fibrotic activity has anti-fibrotic activity. F
Slide 14: CXCR4 and lung fibrosis
CXCR4 and lung fibrosis For personal use only CXCR4 expression is significantly increased in the lung tissue of patients with two lung fibrosis conditions: Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Lung disease (ILD) compared to healthy controls IPF CXCR4 expression not only in circu
Slide 15: AD-114 prevents fibrosis in Bleomycin-induced mouse model of lung fibrosis
AD-114 prevents fibrosis in Bleomycin-induced mouse model of lung fibrosis For personal use only The progression of the lung fibrosis was ameliorated with AD-114, with no significant difference seen from the Day 8 group (start of treatment) and the i-body treated group AMD3100 (CXCR4 antagonist) als
Slide 16: AD-114 prevents fibrosis in Bleomycin-induced mouse model of lung fibrosis
AD-114 prevents fibrosis in Bleomycin-induced mouse model of lung fibrosis For personal use only Normal IPF lung tissue IPF lung tissue + AD-114 lung tissue (lung disease mouse model) dosed for 13 days (dosing started at day 8 in lung disease model) AD-114 reduces collagen content and inflammatory c
Slide 17: AD-114 reduced migration/invasion of IPF lung fibroblasts
AD-114 reduced migration/invasion of IPF lung fibroblasts For personal use only No effect Inhibits slow Inhibits MIGRATION on normal IPF fast IPF AD-114 specifically inhibited migration of slow fibroblasts progressors progressors and rapid IPF fibroblast migration but did not have any effect on norm
Slide 18: CXCR4 and kidney fibrosis
CXCR4 and and kidney fibrosis For personal use only Kidney RENAL FIBROSIS Kidney fibrosis may be caused when the kidneys stop working and eventually transplantation is required. Fibrosis may occur at any stage from the onset of chronic kidney disease (CKD) to end-stage renal disease (ESRD). CXCR4 is
Slide 19: Kidney Fibrosis
Kidney Fibrosis For personal use only CXCR4 is upregulated in fibrotic kidneys of animal and human patients B D 17
Slide 20: AD-114 in Mouse model of Kidney Fibrosis
AD-114 in Mouse model of Kidney Fibrosis For personal use only AD-114 treatment, both preventative and therapeutic, reduced collagen and improved the tissue architecture of folic acid-treatment mice to look similar to control mice AD-114 had a greater effect than that observed with AMD3100 Control F
Slide 21: CXCR4 binding i-body products inhibit key features of the fibrogenic pathway
CXCR4 binding i-body products inhibit key features of the fibrogenic pathway with novel MOA For personal use only Adapted from Wynn JEM 2011 AD-114 & AD-214 19
Slide 22: An i-body to CXCR4 has broad application in treating fibrosis
An i-body to CXCR4 has broad application in treating fibrosis For personal use only AdAlta data shows that an i-body to CXCR4 can improve fibrosis across a range of fibrotic diseases LUNG: Idiopathic Pulmonary Fibrosis KIDNEY: Chronic Kidney Disease EYE: Wet Age Related Macular Degeneration LIVER: N
Slide 23: AD-214 development: key milestones
AD-214 development: key milestones For personal use only 2019 2020 Q3 Q4 Q1 Q2 Q3 Q4 Toxicology studies Clinical study final design and GMP manufacturing Phase I program Bridge Biotherapeutics-BI Adheron-Roche deal done at this stage deal done at this stage 21
Slide 24: Contact us
For personal use only Contact us: Mick Foley, CSO [email protected] www.adalta.com.au
Slide 25: For personal use only
For personal use only. AusBiotech* wy 2019 WF @AUSBIOTECH # AUSBIO19 @ WWWAUSBIOTECHNC.ORG